Corcept Therapeutics Stock Drops After Losing Patent Appeal to Teva
Corcept Therapeutics shares fell sharply to $29.71 in morning trading, following a Federal Circuit ruling affirming no patent infringement by Teva's generic version of Korlym.
/ 5 items
#CORT↓
FDA Contradicts Corcept: Agency Says It Warned Biotech About Drug Rejection Risk
FDA reveals it warned Corcept Therapeutics multiple times about relacorilant's approval issues before the company submitted its Cushing's syndrome drug application.
Corcept's Experimental Drug Shows Promise in Extending Life for Ovarian Cancer Patients
Corcept Therapeutics' (CORT) relacorilant combined with chemotherapy reduced death risk by 35% in platinum-resistant ovarian cancer patients, with FDA decision expected July 2026.
Corcept's Relacorilant Faces FDA Setback for Hypertension Treatment
FDA issues Complete Response Letter for Corcept's relacorilant despite successful trials, requesting more evidence before approval for hypertension treatment in hypercortisolism patients.
The End of an Era: Optime Care Ceases Korlym Distribution Following Corcept’s Decision to End Exclusive Arrangement
The exclusive distributor for Corcept's drug Korlym quit after the company added a new pharmacy. This minor setback delays plans, but analysts advise buying the stock.